Readmissions after cytoreductive surgery and HIPEC

The management of peritoneal metastasis remains controversial. The logo regional treatments are Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and recently the Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Both methods were improved the survival and quality of life in precisions selected patients. On the other hand major progress has been made through nanoparticles. In this short review presented the use of nanoparticles a novel tool increase drug delivery and penetration and may be more effective in patients with peritoneal metastasis.

show abstract

“…HIPEC and PIPAC are two treatments methods that serve this role and have been shown to improve survival [12].…”

Section: Nanoparticles In Hipec/pipacmentioning

confidence: 99%

Nanoparticles in Peritoneal Carcinomatosis

Spiliotis¹,

Nicolas-Jason²,

Hayarpi³

2022

JCMR

View full text Add to dashboard Cite

show abstract

Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: a comprehensive review of clinical outcomes

Karimi,

Shirsalimi,

Sedighi

2024

Front. Surg.

View full text Add to dashboard Cite

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are a pair of relatively modern therapeutic surgical methods in advanced cancerous patients with peritoneal metastasis (PM). The goal of CRS + HIPEC is treatment or to improve survival outcomes, which are linked to high morbidity side effects and complications, even with their possible advantages. Surgical-related, chemotherapy-related, anesthetic-related, gastrointestinal, organs and systemic complications are the categories into which complications are separated according to frequency, risk factors, and effect on patient outcomes. In this narrative review of the literature, the side effects and complications of HIPEC + CRS in cancer patients with PM are examined. The present knowledge on the incidence, frequency, kinds, and risk factors of acute complications following CRS + HIPEC is summarized in this study. This review emphasizes the need for careful patient selection criteria, precise surgical technique, and thorough intraoperative care to reduce or manage these risks. Moreover, it highlights the need for interdisciplinary collaboration in treating these patients. This study aims to know these complications, improve clinical practice, and guide future studies to increase the safety and efficacy of CRS + HIPEC in treating metastatic colorectal cancer.

show abstract

Readmissions after cytoreductive surgery and HIPEC

Cited by 2 publications

References 0 publications

Nanoparticles in Peritoneal Carcinomatosis

Nanoparticles in Peritoneal Carcinomatosis

Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: a comprehensive review of clinical outcomes

Contact Info

Product

Resources

About